WOBURN, Mass.--(BUSINESS WIRE)--Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that second quarter dose sales of SIR-Spheres® microspheres grew 23.7 percent in the Americas region compared to the previous corresponding period for the quarter ending December 31, 2013.
“The Americas team continues to execute our strategic plan to expand the use of SIR-Spheres microspheres in both North and South America and as a result experienced outstanding dose sales growth in the second quarter,” said Mike Mangano, president of Sirtex Medical Inc. “During the remainder of this fiscal year we will focus our efforts on educating physician communities about the latest data that continues to demonstrate the therapy’s safety and efficacy. We look forward to the results of the landmark SIRFLOX study, which completed enrollment in April 2013 and is intended to further illustrate SIR-Spheres microspheres’ role as an earlier standard of care for metastatic colorectal cancer patients.”
Dose sales in all regions rose a combined 18.7 percent during the period. Europe, Middle East and Africa (EMEA) achieved dose sales growth of 5.9 percent and Asia Pacific grew 18.2 percent.
Full mid-year financial results will be released later in the quarter.
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark), Argentina (ANMAT), New Zealand, Switzerland, Turkey, and several other countries in Asia such as India, Korea, Singapore, and Hong Kong. Additionally, SIR-Spheres microspheres are supplied in countries such as Malaysia, Thailand, Taiwan, and Israel. Available at more than 700 treatment centers, over 35,000 doses of SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.